YD Life Science said Tuesday that it has agreed with Fresenius Kabi Korea to sell the latter’s blood bag products in Korea.
Fresenius Kabi’s blood bag is a product sold in more than 100 countries and has excellent quality and competitiveness optimized for storing blood components.
The Fresenius Group, based in Germany, operates more than 3,800 dialysis clinics and 140 hospitals (about 100,000 beds) worldwide. The company recorded an annual sale of 44 trillion won ($39.1 billion) with its medical devices and blood bag products in 2017.
“This deal gives us a good opportunity to grow in a new field,” YD Life Science CEO Lee Jin-woo said. “We will continue to strengthen our medical business by expanding the scope of cooperation with Fresenius, which has a diverse product line.”
<© Korea Biomedical Review, All rights reserved.>